The influence based on CYP3A5 gene polymorphism for calcineurin inhibitors for tailor-made treatment after living-donor liver transplantation.

点击翻译按钮获取中文摘要

Pharmacokinetics of tacrolims in transplantation, especially a body-weight-based dose, often result in marked individual diversity of blood drug concentration. Tacrolimus is a substrate for cytochrome P450(CYP)3A5 having polymorphism. In this study, we genotyped CYP3A5 polymorphism and investigated the association between donor/recipient polymorphisms and pharmacokinetics of tacrolimus in living-donor liver transplantation (LDLT). Furthermore we are trying to introduce a tailor-made therapy based on the donor/recipient CYP3A5 polymorphisms. CYP3A5 polymorphism in the recipient as well as the donor highly influences pharmacokinetics of tacrolimus in the LDLT for the long term. Tailor-made treatment based on CYP3A5 genotype is effective to the reduction of the tacrolimus administration, which may reduce the incidence of drug side effect and ACR.